Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.

Argüelles-Arias, FGuerra Veloz, M FPerea Amarillo, RVilches-Arenas, ACastro Laria, LMaldonado Pérez, BChaaro, DBenítez Roldán, AMerino, VRamírez, GCaunedo Álvarez, ARomero Gómez, M2023-01-252023-01-252017http://hdl.handle.net/10668/11357enErratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.research article28660487open access10.1007/s10620-017-4657-01573-2568PMC6828546https://europepmc.org/articles/pmc6828546?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828546/pdf